APB/Molecular Dynamics Merger Hopes To Challenge Perkin-Elmer
This article was originally published in The Gray Sheet
Amersham Pharmacia Biotech is hoping that its $256 mil. acquisition of Molecular Dynamics will increase sales and distribution opportunities for Molecular's MegaBACE 1000 high-throughput DNA sequencer and create a viable threat to market leader Perkin-Elmer.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.